Guardant Health said preliminary fourth-quarter revenue rose about 39% to roughly $280 million, topping consensus, as oncology test volumes and its Shield screening product expanded. The company reported an expected 79,000 oncology tests (up 38% year over year) and approximately 38,000 Shield screening tests — a near 500% increase from a year earlier. Full-year 2025 revenue is expected to approach $981 million, with strong cash and marketable securities on the balance sheet. Guardant’s results reinforce commercial momentum for liquid biopsy screening and diagnostics across oncology workflows.